Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Roeselare – page 82

2 207 clinical trials in Roeselare, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Roeselare at a glance
2 207
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 207 trials in Roeselare

Open in trial search

Neoplasm

Not yet recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pulmonary hypertension

Not yet recruiting

Discontinuing vs Continuing Riociguat in Chronic Thromboembolic Pulmonary Hypertension Patients After Successful Balloon Pulmonary Angioplasty

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Assistance Publique Hopitaux De Paris

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Anxiety

Not yet recruiting

Efficacy of Etifoxine in Adults with Adjustment Disorder with Anxiety: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etifoxine Hydrochloride
  • Sponsor:Biocodex

Chondrosarcoma+2

Not yet recruiting

Phase I/II Study of Dinutuximab Beta, Irinotecan, and Sirolimus in Children, Adolescents, and Adults with Relapsed or Refractory Bone Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dinutuximab Beta
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Interstitial lung disease

Not yet recruiting

Immunomodulatory Treatment with Prednisone, Azithromycin and Hydroxychloroquine in Patients with Surfactant‑Related Gene Mutation Interstitial Lung Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Assistance Publique Hopitaux De Paris

Bacterial sepsis

Not yet recruiting

Individualized beta‑lactam dosing with piperacillin (drug combination) for ICU patients with sepsis caused by gram‑negative bacteria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone Metasulfobenzoate Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Roeselare

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on bladder cancer, lung cancer, and various blood cancers. Studies evaluate novel combination therapies and targeted treatments.

  • Non-muscle invasive bladder cancer treatment
  • Advanced non-small cell lung cancer therapies
  • Multiple myeloma and leukemia interventions

Research includes innovative immunotherapy combinations and precision medicine approaches.

02 Metabolic Disorders

Clinical investigations targeting hypertriglyceridemia and obesity-related conditions, with emphasis on novel therapeutic approaches.

  • Weight management therapies
  • Type 2 diabetes treatments
  • Lipid disorder interventions

Studies focus on developing safer and more effective treatments for metabolic conditions.

03 Neurological Conditions

Studies examining treatments for Alzheimer's disease and multiple sclerosis, with particular attention to innovative therapeutic approaches.

  • Alzheimer's-related psychosis management
  • Relapsing-remitting multiple sclerosis therapies
  • Neurological disease modifications

Research aims to improve quality of life and disease management for patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.